Attached files
| file | filename |
|---|---|
| 10-Q - FORM 10-Q - Oncotelic Therapeutics, Inc. | b82615e10vq.htm |
| EX-31.2 - EX-31.2 - Oncotelic Therapeutics, Inc. | b82615exv31w2.htm |
| EX-31.1 - EX-31.1 - Oncotelic Therapeutics, Inc. | b82615exv31w1.htm |
| EXCEL - IDEA: XBRL DOCUMENT - Oncotelic Therapeutics, Inc. | Financial_Report.xls |
Exhibit 32.1
Certification
Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
(Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code)
Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
(Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code)
Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section
1350, chapter 63 of title 18, United States Code), the undersigned officers of OXiGENE, Inc.
(the “Company”), do hereby certify, to such officers’ knowledge, that:
The Quarterly Report on Form 10-Q for the six months ended June 30, 2011 (the “Form 10-Q”) of
the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities
Exchange Act of 1934, and the information contained in the Form 10-Q fairly presents, in all
material respects, the financial condition and results of operations of the Company.
| Date: August 12, 2011 | By: | /s/ Peter J. Langecker | ||
| Peter J. Langecker | ||||
| Chief Executive Officer | ||||
| Date: August 12, 2011 | By: | /s/ James B. Murphy | ||
| James B. Murphy | ||||
| Vice President and Chief Financial Officer |
||||
A signed original of this written statement required by Section 906 has been provided to the
Company and will be retained by the Company and furnished to the Securities and Exchange
Commission or its staff upon request.